Comprehensive MALDI mass spectrometry imaging of tumor regions post-neoadjuvant therapy
- PMID: 39976685
- DOI: 10.1007/s00216-025-05785-4
Comprehensive MALDI mass spectrometry imaging of tumor regions post-neoadjuvant therapy
Abstract
The spatial metabolic analysis of tumor tissues following neoadjuvant chemotherapy (NAC) is critical for understanding chemotherapy-induced metabolic changes. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) offers a powerful tool for revealing spatially resolved metabolic profiles within tissues. However, necrotic regions in post-NAC tissues are fragile, creating challenges for sample preparation and MALDI MSI analysis. In this study, we introduce an optimized workflow employing conductive tape to stabilize tissue samples during sectioning and MALDI MSI analysis, preserving necrotic areas while maintaining tissue integrity. Using this technique, we successfully mapped metabolic alterations across necrotic and viable regions of post-NAC tumor tissues, providing new insights into metabolic changes that occur after chemotherapy. Our findings establish MALDI MSI as a valuable tool for spatially resolved metabolomics in post-NAC tumor tissues, offering insights into chemotherapy-induced metabolic changes.
Keywords: Matrix-assisted laser desorption ionization mass spectrometer; Necrotic region; Neoadjuvant chemotherapy; Spatial metabolomics.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: This study was conducted in accordance with ethical standards. The use of human tissue was approved by the Ethics Committee of Huashan Hospital, Fudan University (HIRB: 2017M-003), and informed consent was obtained from the patient. All animal procedures complied with the National Research Council guidelines and were approved by the Animal Care and Use Committee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Source of biological material: Quality control (QC) samples were obtained from 6-week-old male C57 BL/6 mice, provided by the Animal Service Center at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. A tissue sample containing necrotic regions from a patient with colorectal cancer liver metastasis following NAC was collected at Huashan Hospital (Shanghai, China) with informed patient consent. Animal welfare statement: All animal procedures complied with the National Research Council guidelines and were approved by the Animal Care and Use Committee of the institute. Conflict of interest: The authors declare no competing interests.
References
-
- Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. https://doi.org/10.1016/S1470-2045(17)30904-X . - DOI - PubMed
-
- Wang H, Jia H, Gao Y, et al. Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer. Nat Commun. 2022;13(1):7802. https://doi.org/10.1038/s41467-022-35511-y . - DOI - PubMed - PMC
-
- Talarico MCR, Derchain S, Da Silva LF, et al. Metabolomic profiling of breast cancer patients undergoing neoadjuvant chemotherapy for predicting disease-free and overall survival. IJMS. 2024;25(16):8639. https://doi.org/10.3390/ijms25168639 . - DOI - PubMed - PMC
-
- Chen Y, Yin J, Zhao L, et al. Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing. J Transl Med. 2022;20(1):563. https://doi.org/10.1186/s12967-022-03792-y . - DOI - PubMed - PMC
-
- Cao MD, Giskeødegård GF, Bathen TF, et al. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 2012;12:39. https://doi.org/10.1186/1471-2407-12-39 . - DOI - PubMed - PMC
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
